Lixte enters Phase 1b/2 trial of LB-100 + atezolizumab for metastatic colorectal cancer with NKI

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Trial combines Lixte's PP2A inhibitor LB-100 with Roche's atezolizumab; company provides LB-100 only.
Roche provides atezolizumab and financial support; Lixte has no obligation to reimburse trial costs.
Phase 1b/2 study led by Dr. Neeltje Steeghs at NKI in Amsterdam; opens by June 30, 2024.
Patient accrual up to 24 months; maximum 37 metastatic microsatellite stable colorectal cancer patients.
Dose escalation to determine RP2D; expansion phase evaluates safety, tolerability, and pharmacokinetics.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.